QQQ   293.72 (+0.12%)
AAPL   148.31 (+0.19%)
MSFT   254.69 (-0.18%)
META   120.44 (+1.98%)
GOOGL   100.99 (+0.00%)
AMZN   95.50 (-1.08%)
TSLA   194.70 (+0.00%)
NVDA   171.35 (+1.25%)
NIO   12.09 (-5.40%)
BABA   85.94 (-1.85%)
AMD   77.48 (-0.19%)
T   19.19 (-0.47%)
MU   55.49 (-3.75%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.26 (-0.83%)
DIS   98.59 (+0.74%)
AMC   8.17 (+13.00%)
PYPL   78.53 (+0.15%)
PFE   51.08 (+1.90%)
NFLX   316.95 (+3.74%)
QQQ   293.72 (+0.12%)
AAPL   148.31 (+0.19%)
MSFT   254.69 (-0.18%)
META   120.44 (+1.98%)
GOOGL   100.99 (+0.00%)
AMZN   95.50 (-1.08%)
TSLA   194.70 (+0.00%)
NVDA   171.35 (+1.25%)
NIO   12.09 (-5.40%)
BABA   85.94 (-1.85%)
AMD   77.48 (-0.19%)
T   19.19 (-0.47%)
MU   55.49 (-3.75%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.26 (-0.83%)
DIS   98.59 (+0.74%)
AMC   8.17 (+13.00%)
PYPL   78.53 (+0.15%)
PFE   51.08 (+1.90%)
NFLX   316.95 (+3.74%)
QQQ   293.72 (+0.12%)
AAPL   148.31 (+0.19%)
MSFT   254.69 (-0.18%)
META   120.44 (+1.98%)
GOOGL   100.99 (+0.00%)
AMZN   95.50 (-1.08%)
TSLA   194.70 (+0.00%)
NVDA   171.35 (+1.25%)
NIO   12.09 (-5.40%)
BABA   85.94 (-1.85%)
AMD   77.48 (-0.19%)
T   19.19 (-0.47%)
MU   55.49 (-3.75%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.26 (-0.83%)
DIS   98.59 (+0.74%)
AMC   8.17 (+13.00%)
PYPL   78.53 (+0.15%)
PFE   51.08 (+1.90%)
NFLX   316.95 (+3.74%)
QQQ   293.72 (+0.12%)
AAPL   148.31 (+0.19%)
MSFT   254.69 (-0.18%)
META   120.44 (+1.98%)
GOOGL   100.99 (+0.00%)
AMZN   95.50 (-1.08%)
TSLA   194.70 (+0.00%)
NVDA   171.35 (+1.25%)
NIO   12.09 (-5.40%)
BABA   85.94 (-1.85%)
AMD   77.48 (-0.19%)
T   19.19 (-0.47%)
MU   55.49 (-3.75%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.26 (-0.83%)
DIS   98.59 (+0.74%)
AMC   8.17 (+13.00%)
PYPL   78.53 (+0.15%)
PFE   51.08 (+1.90%)
NFLX   316.95 (+3.74%)
NASDAQ:BGNE

BeiGene - BGNE Stock Forecast, Price & News

$194.57
+2.96 (+1.54%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$188.32
$197.84
50-Day Range
$125.51
$207.71
52-Week Range
$118.18
$365.16
Volume
284,746 shs
Average Volume
283,458 shs
Market Capitalization
$20.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$239.50

BeiGene MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
23.1% Upside
$239.50 Price Target
Short Interest
Healthy
1.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of BeiGene in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$10.27 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($17.69) to ($12.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

905th out of 1,047 stocks

Pharmaceutical Preparations Industry

441st out of 512 stocks

BGNE stock logo

About BeiGene (NASDAQ:BGNE) Stock

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Stock News Headlines

Why Shares of BeiGene Were Up Wednesday
SVB Securities Keeps Their Buy Rating on BeiGene (BGNE)
BeiGene (NASDAQ:BGNE) Trading Down 5.6%
BeiGene to Present at Upcoming Investor Conferences
Is This Chinese Pharmaceutical Stock Worth the Risk?
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Company Calendar

Last Earnings
11/04/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/24/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BGNE
Fax
N/A
Employees
8,200
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$239.50
High Stock Price Forecast
$296.00
Low Stock Price Forecast
$210.00
Forecasted Upside/Downside
+23.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-1,413,350,000.00
Net Margins
-171.94%
Pretax Margin
-169.38%

Debt

Sales & Book Value

Annual Sales
$1.18 billion
Book Value
$44.84 per share

Miscellaneous

Free Float
96,032,000
Market Cap
$20.20 billion
Optionable
Optionable
Beta
0.82

Social Links


Key Executives

  • Mr. John V. OylerMr. John V. Oyler (Age 54)
    Co-Founder, Exec. Chairman & CEO
    Comp: $1.75M
  • Dr. Xiaobin Wu Ph.D. (Age 60)
    Pres, COO & GM of China
    Comp: $1.64M
  • Dr. Xiaodong Wang Ph.D. (Age 59)
    Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director
    Comp: $250k
  • Ms. Julia Wang (Age 51)
    CFO & Principal Accounting Officer
    Comp: $798.14k
  • Mr. Wang Lai (Age 45)
    Global Head of R&D
    Comp: $1.13M
  • Dr. Edna Huang M.D. (Age 49)
    Consultant
    Comp: $768.08k
  • Mr. Daniel Maller
    VP of Fin. & Accounting
  • Ms. Mi Zhou
    Sr. Director of Investor Relations
  • Mr. Kevin C. Mannix
    Sr. VP of Investor Relations.
  • Ms. Diana Lee Francis
    VP and Global Head of Quality & Regulatory Compliance













BGNE Stock - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BGNE shares.
View BGNE analyst ratings
or view top-rated stocks.

What is BeiGene's stock price forecast for 2023?

5 analysts have issued 12 month target prices for BeiGene's stock. Their BGNE share price forecasts range from $210.00 to $296.00. On average, they expect the company's share price to reach $239.50 in the next year. This suggests a possible upside of 23.1% from the stock's current price.
View analysts price targets for BGNE
or view top-rated stocks among Wall Street analysts.

How have BGNE shares performed in 2022?

BeiGene's stock was trading at $270.93 at the start of the year. Since then, BGNE shares have decreased by 28.2% and is now trading at $194.57.
View the best growth stocks for 2022 here
.

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our BGNE earnings forecast
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) announced its earnings results on Thursday, November, 4th. The company reported ($4.46) earnings per share for the quarter, topping the consensus estimate of ($4.70) by $0.24. The firm had revenue of $206.44 million for the quarter, compared to analyst estimates of $185.70 million. BeiGene had a negative trailing twelve-month return on equity of 38.92% and a negative net margin of 171.94%.

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by a number of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (4.57%), Baillie Gifford & Co. (3.10%), Temasek Holdings Private Ltd (3.00%), BlackRock Inc. (2.69%), State Street Corp (0.72%) and Price T Rowe Associates Inc. MD (0.43%). Insiders that own company stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends
.

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $194.57.

How much money does BeiGene make?

BeiGene (NASDAQ:BGNE) has a market capitalization of $20.20 billion and generates $1.18 billion in revenue each year. The company earns $-1,413,350,000.00 in net income (profit) each year or ($21.35) on an earnings per share basis.

How many employees does BeiGene have?

The company employs 8,200 workers across the globe.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for the company is www.beigene.com. The company can be reached via phone at 861085148500 or via email at ir@beigene.com.

This page (NASDAQ:BGNE) was last updated on 12/1/2022 by MarketBeat.com Staff